Pegaptanib for neovascular age-related macular degeneration.

@article{Gragoudas2004PegaptanibFN,
  title={Pegaptanib for neovascular age-related macular degeneration.},
  author={Evangelos S. Gragoudas and Anthony P. Adamis and Emmett T. Cunningham and Matthew Feinsod and David R. Guyer},
  journal={The New England journal of medicine},
  year={2004},
  volume={351 27},
  pages={
          2805-16
        }
}
BACKGROUND Pegaptanib, an anti-vascular endothelial growth factor therapy, was evaluated in the treatment of neovascular age-related macular degeneration. METHODS We conducted two concurrent, prospective, randomized, double-blind, multicenter, dose-ranging, controlled clinical trials using broad entry criteria. Intravitreous injection into one eye per patient of pegaptanib (at a dose of 0.3 mg, 1.0 mg, or 3.0 mg) or sham injections were administered every 6 weeks over a period of 48 weeks… CONTINUE READING
Highly Influential
This paper has highly influenced 56 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Highly Cited
This paper has 1,154 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 605 extracted citations

Pegaptanib in the treatment of wet, age-related macular degeneration

International journal of nanomedicine • 2006
View 7 Excerpts
Highly Influenced

Fit for the Eye: Aptamers in Ocular Disorders

Nucleic acid therapeutics • 2016
View 4 Excerpts
Highly Influenced

1,154 Citations

050100'07'10'13'16'19
Citations per Year
Semantic Scholar estimates that this publication has 1,154 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 23 references

VEGF164 is proinflammatory in the diabetic retina.

Investigative ophthalmology & visual science • 2003

VEGF164 is proinflammatory in the diabetic retina.

Investigative ophthalmology & visual science • 2003